Khalifah R G, Todd P, Booth A A, Yang S X, Mott J D, Hudson B G
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City 66160-7421, USA.
Biochemistry. 1996 Apr 16;35(15):4645-54. doi: 10.1021/bi9525942.
Nonenzymatic glycation (Maillard reaction) of long-lived proteins is a major contributor to the pathology of diabetes and possibly aging and Alzheimer's disease. We report here kinetic studies of the glycation of the model protein ribonuclease A by glucose and ribose leading to the formation of antigenic advanced glycation end products ("AGEs"), detectable by AGE-specific polyclonal antibodies, and pentosidine, an acid-stable fluorescent AGE. As anticipated, the kinetics of glycation by ribose were considerably faster than by glucose, and the rate of AGE formation initially increased with increasing sugar concentrations. However, ribose above 0.15 M appeared to paradoxically slow the kinetics of AGE formation, suggesting ribose inhibits the conversion of "early" Amadori rearrangement products to "late" AGEs and thus favors the accumulation of reactive Amadori intermediates. The facile isolation of such protein intermediates was achieved by an "interrupted glycation" protocol which free and reversibly bound (Schiff base) ribose was removed following a short (24h) initial incubation of 0.5 M ribose at 37 degrees C. The kinetics of buildup of the Amadori intermediates and the kinetics of their post-Amadori conversion to antigenic AGEs were independently studied. A rapid and reversible inhibition of the post-Amadori kinetics by free ribose was verified by direct re-addition of ribose to the isolated, sugar-free intermediate. The pH dependence of the kinetics of antigenic AGE formation from such intermediates was measured and exhibited an unusual bell-shaped profile over the pH range of 5.0-9.5 with a maximum near pH 8.0. Aminoguanidine, a pharmacological AGE inhibitor, was found to moderately or weakly inhibit antigenic AGE formation in such post- Amadori steps. The isolation of the glycated ribonuclease intermediate thus simplifies kinetic and mechanistic studies of AGE formation, permits AGE studies in the absence of complications arising from free or Schiff base bound sugar, and provides a novel methodology for evaluating the mechanism and efficacy of therapeutic agents that may inhibit AGE formation.
长寿蛋白质的非酶糖基化(美拉德反应)是导致糖尿病病理以及可能引发衰老和阿尔茨海默病的主要因素。我们在此报告了对模型蛋白核糖核酸酶A与葡萄糖和核糖进行糖基化反应的动力学研究,该反应会导致形成可被AGE特异性多克隆抗体检测到的抗原性晚期糖基化终产物(“AGEs”)以及戊糖苷(一种酸稳定的荧光AGE)。正如预期的那样,核糖的糖基化动力学比葡萄糖快得多,并且AGE形成速率最初随着糖浓度的增加而增加。然而,高于0.15 M的核糖似乎反常地减缓了AGE形成的动力学,这表明核糖抑制了“早期”阿玛多利重排产物向“晚期”AGEs的转化,从而有利于反应性阿玛多利中间体的积累。通过“中断糖基化”方案实现了此类蛋白质中间体的简便分离,即在37℃下将0.5 M核糖进行短时间(24小时)初始孵育后,去除游离且可逆结合(席夫碱)的核糖。分别研究了阿玛多利中间体的积累动力学及其在阿玛多利反应后转化为抗原性AGEs的动力学。通过将核糖直接重新添加到分离出的无糖中间体中,验证了游离核糖对阿玛多利反应后动力学的快速且可逆的抑制作用。测量了从此类中间体形成抗原性AGEs的动力学对pH的依赖性,在5.0 - 9.5的pH范围内呈现出不寻常的钟形曲线,在pH 8.0附近达到最大值。发现氨基胍(一种药物性AGE抑制剂)在这种阿玛多利反应后的步骤中对抗原性AGE形成有中度或轻度抑制作用。因此,糖基化核糖核酸酶中间体的分离简化了AGE形成的动力学和机制研究,允许在不存在游离或席夫碱结合糖引起的复杂情况的条件下进行AGE研究,并为评估可能抑制AGE形成的治疗药物的机制和疗效提供了一种新方法。